MNPR (Monopar Therapeutics) Insider Ownership: 7.48 % (As of Aug. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MNPR Monopar Therapeutics Inc MNPR
33 GF Score
Price $113.39
! 3 Warning Signs
View Full Analysis

What is Monopar Therapeutics Insider Ownership?

Monopar Therapeutics MNPR +2.63% 33 Insider Ownership is 7.48 % as of Aug. 15, 2026. GuruFocus rates MNPR with a GF Score™ of 33/100. The stock has 3 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Monopar Therapeutics's insider ownership is 7.48%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Monopar Therapeutics's Institutional Ownership is 93.15%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Monopar Therapeutics's Float Percentage Of Total Shares Outstanding is 68.35%.

Monopar Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Monopar Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Monopar Therapeutics Insider Ownership Chart

Monopar Therapeutics Historical Data

The historical data trend for Monopar Therapeutics can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 7.94 7.87 7.87 8.01 7.40 7.22 7.22 7.30 7.30 7.48
MNPR
33GF Score
Monopar Therapeutics Inc MNPR
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Monopar Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 7.48 % mean?
Monopar Therapeutics (MNPR) has a Insider Ownership of 7.48 % as of Aug. 15, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Monopar Therapeutics and its competitors.
Is Monopar Therapeutics' Insider Ownership too high?
Monopar Therapeutics' current Insider Ownership is 7.48 %. Overall, Monopar Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Monopar Therapeutics' Insider Ownership compare to DSGN and CLYM?
Monopar Therapeutics' Insider Ownership of 7.48 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Monopar Therapeutics and its competitors. Monopar Therapeutics's current Insider Ownership is 7.48 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monopar Therapeutics stock overvalued right now?
Monopar Therapeutics (MNPR) has a current Insider Ownership of 7.48 %. The current Insider Ownership is 7.48 %. Monopar Therapeutics' overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Monopar Therapeutics (MNPR), the current Insider Ownership is 7.48 % as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Monopar Therapeutics Business Description

Other Exchanges 1IY0:Germany
Address 1000 Skokie Boulevard, Suite 350, Wilmette, IL, USA, 60091
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
33GF Score

Get the complete analysis for MNPR

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$113.39
Price